- First Online:
- 17 Downloads
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain. Etodolac also provides relief of other types of pain, including that arising from gouty conditions and traumatic injury. In all indications, etodolac appears to be at least as effective as other NSAIDs.
The incidence of clinical adverse effects other than abdominal pain and dyspepsia is similar to that observed with placebo, and etodolac has been associated with a low rate of gastrointestinal ulceration and other serious events.
Data from preliminary animal studies have suggested that etodolac may provide more selective inhibition of prostaglandin synthesis at sites of inflammation than some other currently available NSAIDs.
Thus, available evidence indicates that etodolac, with its low incidence of gastrointestinal events, is an effective and well tolerated alternative to other NSAIDs in the treatment of arthritic diseases and pain of various aetiologies and should be considered a first-line therapy.
Etodolac is a pyranocarboxylic acid-derived nonsteroidal anti-inflammatory drug (NSAID), with analgesic activity. In common with other NSAIDs, etodolac inhibits biosynthesis of prostaglandins by inhibition of cyclo-oxygenase. Evidence from animal studies suggests that the drug may preferentially inhibit prostaglandin synthesis at sites of inflammation; macrophage accumulation at inflammatory sites also appears to be inhibited.
The ratio of anti-inflammatory to gastric irritant activity in rats was more favourable for etodolac than for aspirin, sulindac, indomethacin or piroxicam, and studies in healthy subjects and arthritic patients have confirmed that etodolac (in dosages up to 1200 mg/day) causes less faecal blood loss and less endoscopically verified gastroduodenal irritation than aspirin, indomethacin, naproxen and ibuprofen. This low propensity of etodolac to cause gastric irritation, together with its lack of significant effects on renal function, may reflect a selective sparing of cytoprotective gastric mucosal prostaglandins, and of renal prostaglandins, as demonstrated in animals and humans.
Etodolac appeared to reverse the pathological articular changes of established adjuvant arthritis in rats, whereas naproxen or ibuprofen merely inhibited these changes and aspirin had no effect. Moreover, etodolac slowed progression of joint disease in mice with collagen-induced arthritis, a model in which some other NSAIDs have shown little activity. Preliminary evidence of slowing of disease progression in patients with rheumatoid arthritis treated with etodolac has been reported in 1 study. Unlike a number of other NSAIDs, etodolac did not inhibit synthesis of proteoglycan, type II collagen and DNA by chondrocytes in vitro. However it is important to emphasise that these findings require confirmation, in large-scale clinical trials.
A uricosuric effect has been observed in patients with rheumatoid arthritis receiving etodolac in clinical trials.
Peak serum concentrations of around 12 to 15 mg/L and 21 mg/L are achieved within 2 hours of oral administration of etodolac 200 and 400mg, respectively. Concomitant administration of food may decrease the rate, but not the extent, of absorption of etodolac. Etodolac is extensively (> 99%) bound to plasma proteins and has an estimated volume of distribution of 0.41 L/kg. The drug penetrates rapidly into synovial fluid in patients with arthritis and data from animal studies have indicated that the uptake of etodolac may be enhanced in inflamed tissue.
Excretion of etodolac occurs mainly by the renal route, around 60% of a dose being recovered in the urine within 24 hours and 73% within 7 days, mostly in the form of conjugated etodolac and hydroxylated metabolites. The elimination half-life of etodolac is around 6 hours in healthy subjects.
The pharmacokinetic profile of etodolac in elderly subjects and those with impaired renal or hepatic function (including those with end-stage renal failure) is similar to that observed in young healthy subjects. Etodolac is not removed by haemodialysis.
Clinical studies have established that etodolac is an effective analgesic and anti-inflammatory agent in the treatment of rheumatoid arthritis and osteoarthritis. In these indications, etodolac appears to be at least as effective as aspirin and has demonstrated comparable efficacy to other NSAIDs including indomethacin, naproxen, piroxicam, diclofenac and sulindac in small numbers of patients. During long term treatment (⩾ 1 year) the therapeutic efficacy of etodolac was maintained in patients with rheumatoid arthritis or osteoarthritis. Etodolac has been less extensively studied in ankylosing spondylitis, but appeared to be as effective as indomethacin, naproxen or piroxicam.
In postoperative pain etodolac 100 to 400mg provides effective analgesia which is equal or superior to that of aspirin 650mg, while etodolac 400mg was superior to a combination of codeine 60mg and paracetamol 600mg in 1 study.
In painful conditions such as gout, tendinitis, bursitis, acute sports injuries and pain of orthopaedic pathology, etodolac appeared to be as effective as diclofenac, naproxen or piroxicam, but in low back pain it was less effective than piroxicam-β-cyclodextrin.
Etodolac has been well tolerated in clinical trials. As with other NSAIDs, the most common adverse effects are gastrointestinal disturbances (dyspepsia, abdominal pain, nausea; 14% of patients), central nervous system effects (headache, dizziness; 3%) and dermatological reactions (pruritus, rash; 3%). With the exception of abdominal pain and dyspepsia, the incidence of such effects during etodolac treatment was similar to that observed with placebo. The incidence of adverse effects other than dyspepsia does not appear to be increased in elderly patients.
The gastrointestinal tolerability of etodolac is superior to that of aspirin or indomethacin, and at least as good as that of sulindac or piroxicam. In particular, etodolac is associated with a low rate of gastrointestinal ulceration and other serious events. Fewer than 1% of patients withdrew from clinical trials because of altered hepatic, renal or haematological test values.
Dosage and Administration
The recommended adult dosage of etodolac for chronic arthritic pain is 400 to a maximum of 1200 mg/day in divided doses. A dosage of 200 to 400mg every 6 to 8 hours as required is recommended for acute pain. Patients concurrently receiving oral anticoagulants should be monitored for a possible effect on prothrombin time.
Unable to display preview. Download preview PDF.
- Adams L, Neuman RG, Sachs J, Bralow SP. Efficacy and gastric safety of etodolac as determined in culture human gastric and synovial cells. Abstract 19644. Gastroenterology 98(Suppl. 5): 2, 1990Google Scholar
- Arnold JD, Salom IL, Berger AE, Meinders JD, Jacob G, et al. Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. Current Therapeutic Research 37(4): 730–738, 1985Google Scholar
- Bardin T, Lermusiaux JC, Kuntz D. Etodolac in rheumatoid arthritis: a controlled study versus placebo. Abstract 150. Clinical and Experimental Rheumatology 5(Suppl. 2): 201, 1987Google Scholar
- Bilsback P, Roily G, Versichelen L, Meris M, Joubert L. Etodolac in post surgical pain: double-blind dose-ranging study with aspirin and placebo. In Vickers (Ed.) Proceedings of European Academy of Anaesthesiology, pp. 257–260, Springer, New York, 1982Google Scholar
- Bontoux D. Lombo-Radiculalgies: efficacite, tolerance et benefice therapeutique compares de Petodolac (600 mg/j), du diclofenac (150 mg/j) et du placebo. Rhumatologie 42: 201–206, 1990Google Scholar
- Brater DC. Renal safety profile of etodolac. In Etodolac: clinical perspectives in antiarthritic therapy pp. 37–45, Postgraduate Medicine: Customs Communications, New York, 1985Google Scholar
- Brater D. Effect on renal function of a high dose of etodolac (Lodine, Ramodar, Ultradol). Abstract 155. Clinical and Experimental Rheumatology 5(Suppl. 2): 202, 1987Google Scholar
- Briançon D, Peterschmitt J, Laviec G. Double-blind parallel-group evaluation of the safety and efficacy of etodolac capsules compared with piroxicam capsules in patients with rheumatoid arthritis. Acta Therapeutica 17: 35, 1991Google Scholar
- Chiang S, Ermer JC, Kraml M, Sanda M, Conrad K. Steady-state dose-proportionality of etodolac. Abstract 16546. Clinical Pharmacology and Therapeutics 47: 192, 1990Google Scholar
- Davoli L, Ciotti G, Biondi M, et al. Piroxicam-beta-cyclo-dextrin in the treatment of low-back pain. Current Therapeutic Research 46: 940–947, 1989Google Scholar
- Delcambre B. Polyarthrite rhumatoide: efficacite, tolerance et benefice therapeutique compares de l’etodolac (600 mg/j) et de l’indometacine (100 mg/j). Rhumatologie 42: 213–218, 1990Google Scholar
- Doury P, Pattin S, Eulry F. Controlled study of a new non steroidal anti-inflammatory drug (etodolac), against placebo in the treatment of ankylosing spondylitis. In Fostiropoulos GS, et al. (Eds) 11th European Congress of Rheumatology, Athens, 28 Jun–4 Jul 1987. Clinical and Experimental Rheumatology 47, 1987Google Scholar
- Fioravanti A, Vaccai D, Megale F, Dragonetti C, Iudice A, et al. Single-blind, randomized, parallel-group study of etodolac and naproxen in patients with osteoarthritis. Current Therapeutic Research 46(4): 648–653, 1989.Google Scholar
- Fliedner L, Levsky M, Kechejian H, Berger J, Gaston G, et al. Analgesia with etodolac in oral postsurgical pain. Current Therapeutic Research 36(1): 33–45, 1984Google Scholar
- Friedrich E. A comparison of etodolac (Ultradol®) with aspirin and placebo in patients with episiotomy pain. Current Therapeutic Research 33(1): 100–107, 1983Google Scholar
- Gengos D, Sanda M. Long-term effectiveness of etodolac (Lodine, Ramodar, Ultradol) in patients with osteoarthritis. Abstract 158. Clinical and Experimental Rheumatology: 5(Suppl. 2): ? 1987Google Scholar
- Gervais F, Martel RR, Skamene E. The effect of the nonsteroidal anti-inflammatory drug etodolac on macrophage migration in vitro and in vivo. Journal of Immunophar-macology 6(3): 205–214, 1984Google Scholar
- Hutton CE. The effectiveness of 100 and 200mg etodolac (Ultradol), aspirin, and placebo in patients with pain following oral surgery. Oral Surgery, Oral Medicine and Oral Pathology 56(6): 575–580, 1983Google Scholar
- Inoue K, Fujisawa H, Sasaki Y, Nishimura T, Nishimura I, et al. Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac. Arzneimittel-Forschung/Drug Research 41: 228–235, 1991aGoogle Scholar
- Inoue K, Motonaga A, Nishimura T, Yokota M, Miki N, et al. Mechanism of anti-inflammatory action of etodolac. Arzneimittel-Forschung/Drug Research 41: 235–239, 1991bGoogle Scholar
- Jacob GB, Hart KK, Mullane JF, Lutins S, Lee TY. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. Current Therapeutic Research 33(4): 703–713, 1983Google Scholar
- Jacob G, Messina M, Caperton E, Gordon R, Harris G, et al. Safety and efficacy of etodolac, once or twice day, in the treatment of active rheumatoid arthritis. Current Therapeutic Research 37(6): 1124–1129, 1985Google Scholar
- Jacob G, Mullane JF, Sanda M. Long-term treatment with etodolac (Lodine, Ramodar, Ultradol) in patients with rheumatoid arthritis. Abstract 159. Clinical and Experimental Rheumatology 5(Suppl. 2): 203, 1987Google Scholar
- Keiser J, Brady M, Marquis D, Ackerman D. Effect of etodolac and nonsteroidal antiinflammatory drugs (NSAIDs) on the diuretic activity of hydrochlorothiazide (HCTZ) in rats. Abstract. Federation Proceedings 45(3): 1053, 1986Google Scholar
- Kraml M, Cosyns L, Hicks DR, Simon J, Mullane JF, et al. Bioavailability studies with etodolac in dogs and man. Biopharmaceutics and Drug Disposition 5(1): 63–74, 1984Google Scholar
- Lasseter K, Shamblen E, Murdoch A, Marino M, Minor M, et al. Pharmacokinetics of etodolac in patients with hepatic cirrhosis. Abstract 105. Journal of Clinical Pharmacology 28(10): 933, 1988Google Scholar
- Lederman R. A double-blind comparison of etodolac (Lodine®) and high doses of naproxen in the treatment of acute gout. Advances in Therapy 7(6): 344–354, 1990Google Scholar
- Lee DKH. Effect of etodolac on the prostaglandin concentrations in the kidney of the normal rat. Drug Development Research 9(4): 305–311, 1986Google Scholar
- Mauviel A, Redini F, Loyau G, Pujol J-P. Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the nonsteroidal anti-inflammatory drug etodolac I: Collagen synthesis. Agents and Actions 31: 3–4, 1990Google Scholar
- Melarange R, O’Connell C, Gentry C, Blower PR. Gastrointestinal irritancy induced by non-steroidal anti-inflammatory drugs (NSAIDs) in the rat: lack of effects with nabumetone. Abstract 43604. Scandinavian Journal of Rheumatology 19(85): 58, 1990Google Scholar
- Menkes CJ. Periarthrite scapulo-humerale: efficacite, tolerance et benefice therapeutique compares de l’etodolac (600 mg/j) et du piroxicam (40/20 mg/j). Rhumatologie 42: 195–200, 1990Google Scholar
- Mullane JF, Salem S. Double-blind evaluation of the effect of etodolac and placebo on uric acid levels. Current Therapeutic Research 43(3): 552–557, 1988Google Scholar
- Neuman RG, Wilson BD, Barkley M, Kimball ES, Weichman BM, et al. Inhibition of prostaglandin biosynthesis by etodolac. I. Selective activities in arthritis. Agents and Actions 2(1-2): 160–165, 1987Google Scholar
- Norman A, Greenspan A, Jacob G, Salem S, Sanda M, et al. Radiographic findings and evaluation of skeletal changes in patients with rheumatoid arthritis treated with etodolac and aspirin. Abstract 11. American Rheumatism Association 49th Annual Meeting, p. 15, 1985Google Scholar
- Palferman TG, Struthers GR, Williams PI. Double-blind, parallel comparison of etodolac and naproxen in patients with osteoarthritis of the knee. Acta Therapeutica 17: 19, 1991Google Scholar
- Pattin S. Spondylarthrite ankylosante: efficacite, tolerance et benefice therapeutique compares de l’etodolac (600 mg/j) et du piroxicam (20 mg/j). Rhumatologie 42: 207–212, 1990Google Scholar
- Paulsen GA, Baigun S, de Figueiredo JG, de Freitas GG. Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. Current Medical Research and Opinion 12: 401, 1991Google Scholar
- Pena M, Lizarazo H. Double-blind comparison of etodolac and naproxen in patients with osteoarthritis. Acta Therapeutica 17: 5, 1991Google Scholar
- Phadke K, Fouts RL, Parrish JE, Butler LD. Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model. Immunopharma-cology 10: 51–60, 1985Google Scholar
- Sanda M, Collins SH, Mahady J, Huth J, Krantz K. Three-month multicenter study of etodolac (Ultradol®) in patients with osteoarthritis of the hip. Current Therapeutic Research 33(5): 782–792, 1983Google Scholar
- Scott R, Ellis III E, Upton LG. Double-blind evaluation of etodolac (200mg, 400mg) compared with zomepirac (100mg) and placebo on third molar extraction pain. Oral Surgery 62(6): 638–642, 1986Google Scholar
- Shand DG. The pharmacology of etodolac: a review. Etodolac: Clinical Perspectives in Antiarthritic Therapy 16th Congress of Rheumatology, Sydney, Australia, May, 1985, pp. 5–13, Royal Society of Medicine Services Limited, International Congress and Symposium Series, 1985Google Scholar
- Troy S, Sanda M, Dressier D, Chiang S, Latts J. The effect of food and antacid on etodolac bioavailability. Abstract 16547. Clinical Pharmacology and Therapeutics 47: 192, 1990Google Scholar
- Viana de Queiros MF. Double-blind comparison of etodolac and naproxen in the treatment of rheumatoid arthritis. Clinical Therapeutics 13: 38, 1991Google Scholar
- Waltham-Weeks CD. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study. Current Medical Research amLOpinidn 10(8): 540–547, 1987Google Scholar
- Willemin B, Blickle J-F, Meaume S, Zerbe S, Brogard JM. Allergic vasculitis caused by etodolac. The first case (letter). Annales de Medicine Interne 140(6): 529–530, 1989Google Scholar
- Wooley PH, Whalen JD, Zimmerman L, Champion TM. The effect of etodolac on type II collagen-induced arthritis in mice. Agents and Actions 21(3-4): 245–246, 1987Google Scholar